Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03149822 · ClinicalTrials.gov registry record · Phase 1
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT03149822 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 45 participants.
The verdict
NCT03149822, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a phase I/II open-label study designed to evaluate the combination of pembrolizumab and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell carcinoma. Sequential dose escalation of cabozantinib with standard dose pembrolizumab will occur in the phase I dose escalation part of the study to determine the recommended phase 2 dose (RP2D). Subsequently, subjects will receive cabozantinib at the RP2D in combination with pembrolizumab in the phase II dose expansion part of the study.
Interventions
- DRUG Pembrolizumab
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-09-28 |
| Est. Completion | 2024-02-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03149822
The ClinicalTrials.gov registry entry for NCT03149822 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03149822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03149822 about?
NCT03149822 is a clinical study titled "Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma". This is a phase I/II open-label study designed to evaluate the combination of pembrolizumab and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell carcinoma. Sequential dose escalation of cabozantinib with standard dose pembrolizumab will occur in the phase I dose es...
What is the current status of trial NCT03149822?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2017-09-28. Estimated completion is 2024-02-16.
What interventions are being tested in trial NCT03149822?
The interventions under investigation include: Pembrolizumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03149822?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.